MX2009012906A - Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer. - Google Patents

Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer.

Info

Publication number: MX2009012906A
Authority: MX; Mexico
Prior art keywords: cancer; treatment; monoclonal antibodies; antibodies against; against claudin
Prior art date: 2007-05-29

Application number

MX2009012906A

Other languages

English (en)

Spanish (es)

Inventor

Ugur Sahin

Oezlem Tuereci

Dirk Usener

Gunda Brandenburg

Original Assignee

Ganymed Pharmaceuticals Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-29

Filing date

2008-05-27

Publication date

2010-01-25

2008-05-27 Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag

2010-01-25 Publication of MX2009012906A publication Critical patent/MX2009012906A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MX2009012906A 2007-05-29 2008-05-27 Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer. MX2009012906A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US93209907P	2007-05-29	2007-05-29
EP07010622A EP1997832A1 (en)	2007-05-29	2007-05-29	Monoclonal antibodies against Claudin-18 for treatment of cancer
PCT/EP2008/004197 WO2008145338A2 (en)	2007-05-29	2008-05-27	Monoclonal antibodies against claudin-18 for treatment of cancer

Publications (1)

Publication Number	Publication Date
MX2009012906A true MX2009012906A (es)	2010-01-25

Family

ID=38650052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2009012906A MX2009012906A (es)	2007-05-29	2008-05-27	Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer.

Country Status (24)

Country	Link
US (1)	US8425902B2 (da)
EP (4)	EP1997832A1 (da)
JP (3)	JP5816431B2 (da)
KR (3)	KR101585990B1 (da)
CN (2)	CN103694353B (da)
BR (1)	BRPI0811907A2 (da)
CA (1)	CA2687206C (da)
DK (1)	DK3401334T5 (da)
ES (2)	ES2675375T3 (da)
FI (1)	FI3401334T3 (da)
HR (1)	HRP20230282T3 (da)
HU (1)	HUE061795T2 (da)
IL (3)	IL201666A (da)
LT (1)	LT3401334T (da)
MX (1)	MX2009012906A (da)
NZ (1)	NZ581365A (da)
PL (1)	PL3401334T3 (da)
PT (1)	PT3401334T (da)
RS (1)	RS64065B1 (da)
RU (2)	RU2571923C2 (da)
SG (1)	SG183773A1 (da)
SI (1)	SI3401334T1 (da)
WO (1)	WO2008145338A2 (da)
ZA (1)	ZA200907675B (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6358588A (ja) *	1986-08-29	1988-03-14	Toshiba Corp	バ−コ−ド読取装置
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) *	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
CA2711843C (en)	2007-12-20	2018-11-13	Laboratory Corporation Of America Holdings	Her-2 diagnostic methods
MX2010011955A (es)	2008-04-29	2011-01-21	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
SG191625A1 (en)	2008-06-03	2013-07-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
KR20110016958A (ko)	2008-06-03	2011-02-18	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
NZ590074A (en)	2008-07-08	2012-12-21	Abbott Lab	Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2438442B1 (en)	2008-12-01	2017-08-09	Laboratory Corporation of America Holdings	Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
EP2387711B1 (en)	2009-01-15	2015-04-22	Laboratory Corporation of America Holdings	Methods of determining patient response by measurement of her-3
MX361432B (es)	2009-02-20	2018-12-05	Ganymed Pharmaceuticals Ag	Métodos para diagnóstico del cáncer.
WO2010127294A2 (en) *	2009-05-01	2010-11-04	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
JP2013503607A (ja)	2009-09-01	2013-02-04	アボット・ラボラトリーズ	二重可変ドメイン免疫グロブリンおよびその使用
UY32948A (es)	2009-10-15	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
NO2499161T3 (da)	2009-11-11	2018-02-03
JP6199036B2 (ja)	2010-03-16	2017-09-20	バイオエヌテックアーゲーＢｉｏＮＴｅｃｈＡＧ	自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種
EP2366709A1 (en) *	2010-03-16	2011-09-21	BioNTech AG	Tumor vaccination involving a humoral immune response against self-proteins
EP2404936A1 (en) *	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2012018790A2 (en)	2010-08-03	2012-02-09	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
WO2012027570A2 (en)	2010-08-26	2012-03-01	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
US9592331B2 (en) *	2011-02-07	2017-03-14	Aggamin Llc	Methods and systems for treating eclampsia or pre-eclampsia
AU2012249454B2 (en) *	2011-04-29	2016-03-24	Apexigen, Inc.	Anti-CD40 antibodies and methods of use
UA127584C2 (uk)	2011-05-13	2023-10-25	Астеллас Фарма Інк.	Антитіла для лікування ракових захворювань, при яких експресується клаудин 6
CN104159920A (zh)	2011-12-30	2014-11-19	艾伯维公司	针对il-13和/或il-17的双重可变结构域免疫球蛋白
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
EP4364756A3 (en) *	2012-05-23	2024-07-31	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP2852409B1 (en)	2012-05-23	2020-03-25	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) *	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en)	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AR093311A1 (es)	2012-11-01	2015-05-27	Abbvie Inc	Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4)
CA3169263A1 (en) *	2012-11-13	2014-05-22	Astellas Pharma Inc.	Agents for treatment of claudin expressing cancer diseases
RS63738B1 (sr) *	2013-02-20	2022-12-30	Astellas Pharma Inc	Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
WO2014127785A1 (en) *	2013-02-20	2014-08-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CA2904448A1 (en)	2013-03-15	2014-09-18	Tariq Ghayur	Dual specific binding proteins directed against il-1.beta. and/or il-17
WO2014146672A1 (en)	2013-03-18	2014-09-25	Ganymed Pharmaceuticals Ag	Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015014376A1 (en)	2013-07-31	2015-02-05	Biontech Ag	Diagnosis and therapy of cancer involving cancer stem cells
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
WO2016165762A1 (en) *	2015-04-15	2016-10-20	Ganymed Pharmaceuticals Ag	Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Claudin-18.2-specific immunoreceptors and t cell epitopes
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3538141A4 (en) *	2016-11-10	2020-07-15	Merck Sharp & Dohme Corp.	ILT3 LIGAND
US11352436B2 (en) *	2017-02-10	2022-06-07	Washington University	Antibodies to TIP1 and methods of use thereof
US20180298094A1 (en) *	2017-04-17	2018-10-18	Ksl Biomedical Llc	Monoclonal antibodies targeted to human taxilin alpha and methods for use of same
CN110945024B (zh) *	2017-04-18	2023-05-12	古德T细胞有限公司	Lrig-1蛋白特异性结合分子及其用途
CN107779500A (zh) *	2017-10-25	2018-03-09	上海药明生物技术有限公司	一种快速获取大鼠杂交瘤细胞单克隆抗体序列的测序方法及引物序列
AU2019232762B2 (en)	2018-03-08	2023-11-16	Phanes Therapeutics, Inc.	Anti-claudin 18.2 antibodies and uses thereof
CR20200465A (es) *	2018-03-13	2020-11-17	Tust Therapeutics Ltd	Agentes anticuerpos anti-cd25
CA3087423A1 (en)	2018-03-14	2019-09-19	Beijing Xuanyi Pharmasciences Co., Ltd.	Anti-claudin 18.2 antibodies
WO2020043044A1 (zh) *	2018-08-27	2020-03-05	南京圣和药业股份有限公司	一种抗Claudin18.2抗体及其应用
US20210380680A1 (en) *	2018-12-07	2021-12-09	ZLlP HOLDING LIMITED	Anti-claudin antibodies and uses thereof
SG11202106534RA (en) *	2018-12-28	2021-07-29	Nanjing Genscript Biotech Co Ltd	Claudin18.2 binding moieties and uses thereof
JP7562528B2 (ja) *	2018-12-28	2024-10-07	四川科倫博泰生物医薬股▲フン▼有限公司	抗体及びその用途
CN111434692B (zh) *	2019-01-15	2021-12-31	浙江道尔生物科技有限公司	抗cld18a2纳米抗体及其应用
CN109762067B (zh) *	2019-01-17	2020-02-28	北京天广实生物技术股份有限公司	结合人Claudin 18.2的抗体及其用途
SG11202108398YA (en) *	2019-02-01	2021-08-30	Novarock Biotherapeutics Ltd	Anti-claudin 18 antibodies and methods of use thereof
TWI848090B (zh) *	2019-04-01	2024-07-11	大陸商江蘇恆瑞醫藥股份有限公司	密蛋白抗體及其應用
CN111978402B (zh) *	2019-05-24	2022-06-28	三优生物医药(上海)有限公司	新型cldn18.2结合分子
EP3978532A4 (en) *	2019-05-24	2023-10-18	Sanyou Biopharmaceuticals Co., Ltd.	NEW BINDING MOLECULE CLDN18.2
WO2021011885A1 (en)	2019-07-17	2021-01-21	The Regents Of The University Of California	Claudin18 antibodies and methods of treating cancer
BR112022003147A2 (pt) *	2019-08-20	2022-05-17	Suzhou Transcenta Therapeutics Co Ltd	Novos anticorpos anti-cldn18.2
CN112574307B (zh) *	2019-09-29	2023-11-28	迈威(上海)生物科技股份有限公司	抗人Claudin18.2抗体及其应用
WO2021111003A1 (en)	2019-12-06	2021-06-10	SOTIO a.s.	Humanized cldn18.2 antibodies
WO2021130291A1 (en)	2019-12-23	2021-07-01	SOTIO a.s.	Tumor-specific claudin 18.2 antibodies
CN117343186A (zh) *	2020-01-03	2024-01-05	上海恺兴诊断技术有限公司	抗Claudin18.2的抗体及其应用
US20240043527A1 (en)	2020-03-30	2024-02-08	BioNTech SE	Rna compositions targeting claudin-18.2
CN113493515B (zh) *	2020-04-02	2023-03-28	广东菲鹏制药股份有限公司	抗cldn18a2的抗体以及治疗肿瘤的药物
AU2021270940A1 (en) *	2020-05-15	2022-12-15	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Antibody drug conjugate, preparation method therefor and use thereof
CN111808194B (zh) *	2020-07-13	2021-04-20	北京凯因科技股份有限公司	一种结合密蛋白的用于治疗癌症的人源化抗体
CN114222761B (zh) *	2020-07-14	2024-02-20	浙江道尔生物科技有限公司	一种抗cld18a2的单域抗体
WO2022122709A1 (en)	2020-12-07	2022-06-16	Sotio Biotech A.S.	Antibody-drug conjugates based on humanized cldn18.2 antibodies
CA3203105A1 (en) *	2020-12-22	2022-06-30	Michael H. Cardone	Methods and compositions related to bcl2 and bim heterodimer antibodies
KR20230124037A (ko)	2020-12-23	2023-08-24	소티오 바이오테크 에이.에스.	종양 특이적 claudin 18.2 항체-약물 접합체
KR20240149438A (ko)	2022-02-27	2024-10-14	베링거 인겔하임 인터내셔날 게엠베하	Cd277 및 종양-항원에 대한 이중특이적 항체
CN114836388A (zh) *	2022-06-07	2022-08-02	江苏亲科生物研究中心有限公司	Claudin18.2单克隆抗体及其制备方法和用途
WO2024074211A1 (en)	2022-10-06	2024-04-11	BioNTech SE	Rna compositions targeting claudin-18.2
WO2024074634A1 (en)	2022-10-06	2024-04-11	BioNTech SE	Rna compositions targeting claudin-18.2

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4954617A (en)	1986-07-07	1990-09-04	Trustees Of Dartmouth College	Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US5013653A (en)	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
JPH02500329A (ja)	1987-05-21	1990-02-08	クリエイテイブ・バイオマリキユールズ・インコーポレーテツド	ターゲット化多機能蛋白質
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
AU639532B2 (en)	1989-12-27	1993-07-29	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Diagnostic probe for detecting human stomach cancer
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
GB9223377D0 (en)	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
AU8470301A (en)	2000-08-03	2002-02-18	Wim-Van Schooten	Production of humanized antibodies in transgenic animals
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
MXPA03004793A (es)	2000-11-30	2004-12-03	Medarex Inc	Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
RU2005100777A (ru) *	2002-06-14	2005-08-27	Иммуномедикс, Инк. (Us)	Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы
WO2004029207A2 (en) *	2002-09-27	2004-04-08	Xencor Inc.	Optimized fc variants and methods for their generation
JP4662473B2 (ja)	2002-10-17	2011-03-30	ゲンマブエー／エス	Ｃｄ２０に対するヒトモノクローナル抗体
DE10254601A1 (de) *	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20050255041A1 (en)	2004-05-13	2005-11-17	Arius Research, Inc.	Cancerous disease modifying antibodies
EP1954272A2 (en) *	2005-10-31	2008-08-13	Bayer Pharmaceuticals Corporation	Treatment of cancer with sorafenib
EP1790664A1 (en) *	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer

2007
- 2007-05-29 EP EP07010622A patent/EP1997832A1/en not_active Withdrawn
2008
- 2008-05-27 ES ES08758782T patent/ES2675375T3/es active Active
- 2008-05-27 HU HUE18168460A patent/HUE061795T2/hu unknown
- 2008-05-27 LT LTEP18168460.6T patent/LT3401334T/lt unknown
- 2008-05-27 RU RU2009149205/10A patent/RU2571923C2/ru active
- 2008-05-27 KR KR1020097024616A patent/KR101585990B1/ko active IP Right Grant
- 2008-05-27 RU RU2015149617A patent/RU2682285C2/ru active
- 2008-05-27 BR BRPI0811907-4A2A patent/BRPI0811907A2/pt not_active Application Discontinuation
- 2008-05-27 CA CA2687206A patent/CA2687206C/en active Active
- 2008-05-27 SI SI200832208T patent/SI3401334T1/sl unknown
- 2008-05-27 US US12/601,488 patent/US8425902B2/en active Active
- 2008-05-27 RS RS20230214A patent/RS64065B1/sr unknown
- 2008-05-27 EP EP08758782.0A patent/EP2152754B8/en active Active
- 2008-05-27 PT PT181684606T patent/PT3401334T/pt unknown
- 2008-05-27 NZ NZ581365A patent/NZ581365A/en unknown
- 2008-05-27 SG SG2012063251A patent/SG183773A1/en unknown
- 2008-05-27 KR KR1020157003504A patent/KR101693365B1/ko active IP Right Grant
- 2008-05-27 MX MX2009012906A patent/MX2009012906A/es active IP Right Grant
- 2008-05-27 EP EP23155995.6A patent/EP4242236A3/en active Pending
- 2008-05-27 WO PCT/EP2008/004197 patent/WO2008145338A2/en active Application Filing
- 2008-05-27 CN CN201310574213.0A patent/CN103694353B/zh active Active
- 2008-05-27 EP EP18168460.6A patent/EP3401334B1/en active Active
- 2008-05-27 DK DK18168460.6T patent/DK3401334T5/da active
- 2008-05-27 PL PL18168460.6T patent/PL3401334T3/pl unknown
- 2008-05-27 KR KR1020167036984A patent/KR101751965B1/ko active IP Right Grant
- 2008-05-27 ES ES18168460T patent/ES2940775T3/es active Active
- 2008-05-27 FI FIEP18168460.6T patent/FI3401334T3/fi active
- 2008-05-27 JP JP2010509723A patent/JP5816431B2/ja active Active
- 2008-05-27 HR HRP20230282TT patent/HRP20230282T3/hr unknown
- 2008-05-27 CN CN2008800180365A patent/CN101687929B/zh active Active
2009
- 2009-10-21 IL IL201666A patent/IL201666A/en active IP Right Grant
- 2009-11-02 ZA ZA2009/07675A patent/ZA200907675B/en unknown
2014
- 2014-07-24 JP JP2014150605A patent/JP5995919B2/ja active Active
2015
- 2015-05-07 IL IL238668A patent/IL238668A0/en unknown
- 2015-05-07 IL IL238667A patent/IL238667A0/en active IP Right Grant
2016
- 2016-08-23 JP JP2016162892A patent/JP6337053B2/ja active Active

Also Published As

Publication number	Publication date
KR101693365B1 (ko)	2017-01-06
RU2015149617A (ru)	2019-01-14
EP1997832A1 (en)	2008-12-03
RU2009149205A (ru)	2011-07-10
CN103694353B (zh)	2017-12-12
SG183773A1 (en)	2012-09-27
JP2010528075A (ja)	2010-08-19
KR20170005160A (ko)	2017-01-11
HUE061795T2 (hu)	2023-08-28
AU2008256489A1 (en)	2008-12-04
SI3401334T1 (sl)	2023-05-31
PT3401334T (pt)	2023-03-27
ZA200907675B (en)	2011-04-28
NZ581365A (en)	2012-02-24
ES2675375T3 (es)	2018-07-10
CA2687206A1 (en)	2008-12-04
EP2152754B1 (en)	2018-04-25
RU2571923C2 (ru)	2015-12-27
EP3401334B1 (en)	2023-02-15
WO2008145338A2 (en)	2008-12-04
RU2015149617A3 (da)	2019-02-04
IL201666A0 (en)	2010-05-31
KR101751965B1 (ko)	2017-07-11
EP4242236A2 (en)	2023-09-13
JP6337053B2 (ja)	2018-06-06
EP4242236A3 (en)	2023-11-22
KR101585990B1 (ko)	2016-01-19
LT3401334T (lt)	2023-03-27
EP3401334A1 (en)	2018-11-14
IL238667A0 (en)	2015-06-30
RS64065B1 (sr)	2023-04-28
JP2015007053A (ja)	2015-01-15
CN101687929B (zh)	2013-11-13
HRP20230282T3 (hr)	2023-05-12
BRPI0811907A2 (pt)	2014-11-18
US8425902B2 (en)	2013-04-23
US20100166779A1 (en)	2010-07-01
DK3401334T5 (da)	2024-09-23
ES2940775T3 (es)	2023-05-11
KR20100021573A (ko)	2010-02-25
RU2682285C2 (ru)	2019-03-18
EP2152754A2 (en)	2010-02-17
CN103694353A (zh)	2014-04-02
JP5995919B2 (ja)	2016-09-21
EP2152754B8 (en)	2018-07-04
PL3401334T3 (pl)	2023-05-15
DK3401334T3 (da)	2023-03-27
WO2008145338A3 (en)	2009-02-12
JP5816431B2 (ja)	2015-11-18
IL238668A0 (en)	2015-06-30
JP2017048170A (ja)	2017-03-09
CA2687206C (en)	2019-07-16
CN101687929A (zh)	2010-03-31
KR20150023951A (ko)	2015-03-05
FI3401334T3 (fi)	2023-03-17
IL201666A (en)	2016-03-31

Publication	Publication Date	Title
MX2009012906A (es)	2010-01-25	Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer.
MX2020011789A (es)	2020-11-24	Anticuerpos monoclonales contra claudina-18 para el tratamiento de cancer.
EP4331578A3 (en)	2024-06-05	Drug conjugates comprising antibodies against claudin 18.2
MX2020011796A (es)	2020-12-07	Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2019013723A (es)	2020-07-20	Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2009009816A (es)	2009-11-23	Anticuerpos monoclonales para el tratamiento del cancer.
MX357010B (es)	2018-06-22	Anticuerpos monoclonales para tratamiento de cancer.
AU2016204376A1 (en)	2016-07-14	MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2007133822A8 (en)	2009-07-23	Gitr antibodies for the treatment of cancer
JOP20220013A1 (ar)	2023-01-30	علاج توليفي ينطوي على استخدام الأجسام المضادة ضد claudin 18.2 ومثبطات نقاط الفحص المناعي لعلاج السرطان
MX337586B (es)	2016-03-11	Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta.
EP4364756A3 (en)	2024-07-31	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2009154790A8 (en)	2010-02-11	Novel metastasis suppressor genes and uses thereof
MX2023011145A (es)	2023-10-05	Terapia de combinacion que implica anticuerpos contra claudina 18.2 para el tratamiento del cancer.

Legal Events

Date	Code	Title	Description
2010-08-31	HH	Correction or change in general
2012-01-31	FG	Grant or registration